UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

(Rule14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)

of the

Securities Exchange Act of 1934

(Amendment No. ___ )

Filed by the Registrant ☒                             [X]

Filed by a Party other than the Registrant ☐[ ]

Check the appropriate box:

Meridian Bioscience, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

3471 River Hills Drive

Cincinnati, Ohio 45244

www.meridianbioscience.com

Notice of Annual Meeting of Shareholders

and Proxy Statement

Dear Shareholders:

On behalf of the Board of Directors, I invite you to attend our Annual Meeting of Shareholders on January 29, 202026, 2022 at 2:00 p.m. Eastern Time. This year’s Annual MeetingTime, which will be conducted asheld virtually. We believe that hosting a virtual meeting of shareholders, a format that we believe will provideprovides expanded access, improved communication and cost savings to our shareholders and the Company.Company, and also aligns with our interests in the health and safety of our shareholders and employees during this time when COVID-19 remains a concern. You will be able to attend the Annual Meeting online, vote your shares electronically and submit your questions during the Annual Meeting by visitingwww.virtualshareholdermeeting.com/VIVO2020VIVO2022. There will not be a physical meeting location and you will not be able to attend the Annual Meeting in person.

This booklet includes the formal notice of the meeting and the proxy statement. The proxy statement tells you more about the agenda and procedures for the meeting. It also describes how the Board operates and gives personal information about our director candidates.

Pursuant to the Securities and Exchange Commission rulerules allowing companies to furnish proxy materials to shareholders over the internet, a Notice of Internet Availability of Proxy Materials (the “Notice”) was sent to shareholders on or about December 18, 2019.15, 2021. The Notice contains information on how to access copies of the proxy materials and vote your shares.

Whether or not you plan tovirtually attend the meeting, please cast your proxy vote promptly, either online, over the phone or by returning your signed and dated proxy card in the enclosed envelope.

Sincerely yours,

/s/ David C. Phillips

David C. Phillips

Chairman of the Board

December 18, 201915, 2021

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS

FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 29, 202026, 2022

Date:

January 29, 2020

Time:

2:00 p.m., Eastern Standard Time

Place:

Online atwww.virtualshareholdermeeting.com/VIVO2020

Purpose:

Only shareholders of record on December 5, 2019 may vote at the meeting. The approximate mailing date of thisThis proxy statement and accompanying proxy card is December 18, 2019.our 2021 Annual Report to Shareholders are available at www.proxyvote.com

Your vote is important. Whether or not you plan to virtually attend the 2020 annual meeting, please cast your proxy vote promptly, either online, over the phone or by returning your signed and dated proxy card in the enclosed envelope.

By order of the Board of Directors,

/s/ Bryan T. Baldasare

Bryan T. Baldasare

Secretary

December 18, 2019

Table of Contents

Meridian makes available, free of charge on its website, all of its filings that are made electronically with the Securities and Exchange Commission (“SEC”), including Forms10-K,10-Q10-K, 10-Q and8-K. These filings are also available on the SEC’s website (www.sec.gov)(www.sec.gov). To access these filings, go to our website (www.meridianbioscience.com)(www.meridianbioscience.com). Copies of Meridian’s Annual Report on Form10-K for the fiscal year ended September 30, 2019,2021, including consolidated financial statements and schedules thereto, filed with the SEC, are also available without charge to shareholders upon written request addressed to:

Bryan T. BaldasareCharles Wood, Jr.

Executive Vice President, Chief Financial Officer and SecretaryInvestor Relations

Meridian Bioscience, Inc.

3471 River Hills Drive

Cincinnati, Ohio 45244

MERIDIAN BIOSCIENCE, INC.

3471 River Hills Drive

Cincinnati, Ohio 45244

Telephone (513)271-3700

P R O X Y    S T A T E M E N T

Annual Meeting of Shareholders

January 26, 2022

January 29, 2020

GENERAL INFORMATION

Who may vote

Shareholders of Meridian, as recorded in our stock register on December 5, 2019,2, 2021, may vote at the meeting. As of that date, Meridian had 42,827,25843,512,743 shares of common stock outstanding.

Location of Annual Meeting

The Annual Meeting will again be conducted as a virtual meeting of shareholders by means of a live webcast. We believe that hosting a virtual meeting will enableprovides greater shareholder attendance and participation from any location, improved communication and cost savings to our shareholders.shareholders and Company, and also aligns with our interests in the health and safety of our shareholders and employees during this time when COVID-19 remains a concern. By visitingwww.virtualshareholdermeeting.com/VIVO2020VIVO2022, you will be able to attend the Annual Meeting, vote your shares, and submit your questions during the meeting via the internet. There will not be a physical meeting location and you will not be able to attend in person. We invite you to attend the Annual Meeting and request that you vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may vote by internet, by telephone, or, if you requested and received paper copies of the proxy materials by mail, you may also vote by completing and mailing your proxy card.

How to vote

You may vote electronically at the meeting, by telephone, online, or by completing and returning a proxy card. We recommend you vote by proxy even if you plan to attend the virtual meeting. You can always change your vote, by voting electronically, at the meeting.

How proxies work

Meridian’s Board of Directors is asking for your proxy. Giving us your proxy means you authorize us to vote your shares at the meeting in the manner you direct. You may vote for all, some or none of our director candidates. You may also vote for or against the other proposals or abstain from voting.

If you complete your proxy online, over the phone or sign and return the enclosed proxy card but do not specify how to vote, we will vote your shares in favor of: (i) the election of our director candidates; (ii) the ratification of the appointment of Grant ThorntonErnst & Young LLP as Meridian’s independent registered public accountantsaccounting firm for fiscal year 2020;2022; and (iii) our executive compensation. If any other matters come before the meeting or any continuation, postponement or adjournment, thereof, each proxy will be voted in the discretion of the individuals named as proxies on the card.

You may receive more than one proxy or voting card depending on how you hold your shares. Shares registered in your name are covered by one card. If you hold shares through someone else, such as a stockbroker, bank or nominee, you may get material from them asking how you want to vote.

Stockbrokers, banks and nominees holding shares for beneficial owners must vote those shares as instructed by you. If the stockbroker, bank or nominee has not received instructions from you, the beneficial owner, the

stockbroker, bank or nominee generally has discretionary voting power only with respect to the ratification of appointment of the independent registered public accountants.accounting firm. However, a stockbroker, bank or nominee does not have discretion to vote for or against the election of directors and certain other matters subject to a vote if they have not received voting instructions from you. In order to avoid a brokernon-vote of your shares on the election of directors and the other matters subject to a vote, you must send voting instructions to your stockbroker, bank or nominee.

Solicitation of proxies

Solicitation of proxies is being made by management at the direction of Meridian’s Board of Directors, without additional compensation, through the mail, in person or by telephone. The cost of preparing and mailing the Notice and the proxy statement and any accompanying material will be borne by Meridian. In addition, Meridian will request brokers and other custodians, nominees and fiduciaries to forward proxy soliciting material to the beneficial owners of shares held of record, and Meridian will reimburse them for their expenses in so doing.related expenses.

Revoking a proxy

You may revoke your proxy before it is voted by submitting a new proxy with a later date, by voting electronically at the meeting or by notifying Meridian’s SecretaryVice President, Investor Relations in writing at the address under “Questions” on page 3134 of this proxy statement.

Quorum

In order to carry on the business of the meeting, we must have a quorum. This means at least a majority of the outstanding shares eligible to vote must be represented at the meeting, either by proxy or in person.

Votes needed

The eight director candidates receiving the most votes will be elected to fill the seats on the Board (Proposal No. 1). The ratification of appointment of accountantsaccounting firm (Proposal No. 2), and the approval on an advisory basis of our executive compensation (Proposal No. 3) require the favorable vote of a majority of the votes cast. Only votes for or against these proposals count, with abstentions not being counted either for or against these proposals.

Abstentions and brokernon-votes count for quorum purposes but as indicated above, will not count for voting purposes. Brokernon-votes occur when a broker returns a proxy card but does not have authority to vote on a particular proposal.

Other matters

Any other matters considered at the meeting, including any continuation, postponement or adjournment, will require the affirmative vote of a majority of the votes cast.

The Virtual Meeting

We will be hosting the Annual Meeting only by means of a live webcast. There will not be a physical meeting location and you will not be able to attend the meeting in person. Please be assured that you will be afforded the same rights and opportunities to participate in the virtual meeting and ask questions as you would at anin-person meeting. By going towww.virtualshareholdermeeting.com/VIVO2020VIVO2022, you will be able to listen to the Annual Meeting, submit questions and vote. If you wish to listen to the Annual Meeting, but do not wish to submit questions or vote during the Annual Meeting, you may go towww.virtualshareholdermeeting.com/VIVO2020VIVO2022 and log in as a guest. We will post a recording of the meeting, including appropriate questions received during the meeting and the Company’s answers, on the investor page of www.meridianbioscience.com as soon as practicable after the meeting.

The Annual Meeting will start at 2:00 p.m. (Eastern Time) on January 29, 2020.26, 2022. We encourage you to access the meeting website prior to the start time to allow time for check in.check-in. If you encounter any technical or logistical issues or difficulties withaccessing the virtual meeting platform onduring the check-in or meeting day,time, please call the following applicabletechnical support number for technical support:800-586-1548 (United States);303-562-9288 (International).that will be posted on the Virtual Shareholder Meeting login page.

You do not need to register to attend the Annual Meeting webcast. Follow the instructions on your Notice of Internet Availability or proxy card (if you requested and received a printed copy of the proxy materials) to access the Annual Meeting.

If you wish to submit a question the day of the Annual Meeting, you may log in to the virtual meeting platform atwww.virtualshareholdermeeting.com/VIVO2020VIVO2022, type your question into the “Ask a Question” field, and click “Submit.” Questions pertinent to meeting matters will be answered during the Annual Meeting, subject to time constraints. Questions regarding personal matters, including those related to employment, are not pertinent to annual meeting matters and, therefore, will not be answered. We will post on the Virtual Meeting page additional guidelines for shareholder questions, rules around what types of questions are allowed, and any other procedures for how questions and comments will be recognized.

The Nominating and Corporate Governance Committee of the Board of Directors has nominated forre-election the following current directors: James M. Anderson, Anthony P. Bihl III, Dwight E. Ellingwood, Jack Kenny, John C. McIlwraith, David C. Phillips, John M. Rice, Jr., Catherine A. Sazdanoff, and Felicia Williams.

Proxies solicited by the Board will be voted for the election of these nominees. All directors elected at the Annual Shareholders’ Meeting will be elected to hold office until the next annual meeting. In voting to elect directors, shareholders are entitled to cumulate their votes and to give one candidate a number of votes equal to the number of directors to be elected multiplied by the number of shares held by the shareholder, or to distribute their votes on the same principle among as many candidates as the shareholder sees fit. In order to invoke cumulative voting, notice of cumulative voting must be given in writing by a shareholder to the Chief Executive Officer, a Vice President or the Assistant Secretary of Meridian not less than 48 hours prior to the Annual Shareholders’ Meeting. The proxies solicited include discretionary authority to cumulate votes.

All Meridian directors are elected forone-year terms. Personal information on each of our nominees is given below.

If a director nominee becomes unavailable before the election, your proxy card authorizes us to vote for a replacement nominee if the Board names one.

The Board recommends that you voteFOR each of the following candidates:

Anthony P. Bihl III

Director since 2020

Age: 65

	Anthony P. Bihl served as Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President of American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont. Mr. Bihl is a director and Chairman of the Board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock, and Sonendo, Inc. (NYSE:SONX), a leading dental technology company that began trading on the New York Stock Exchange on October 29, 2021. In addition, Mr. Bihl currently serves on the boards of directors of Flowonix Medical Inc., a privately-held company that develops and markets targeted drug delivery platforms (since July 2020). Mr. Bihl previously served as a member of the board of directors of Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020 and prior to March 2016, served on the board of directors of Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra. The Board believes that Mr. Bihl is well qualified to serve on Meridian’s Board considering his more than 30 years of experience in the medical device industry in a variety of operations, finance and general management roles.
Dwight E. Ellingwood Director since 2014 Age: 6769		Dwight E. Ellingwood serves as Chairman of the Nominating and Corporate Governance Committee. Withhas over 3540 years of experience in health care strategy, planning and business development, he currently isand since 2017 has served as a teaching professorTeaching Professor and associate directorAssociate Director for practitioner experiencePractitioner Experience in the GraduateMasters Program of the Department of Health Services Administration at Xavier University in Cincinnati, Ohio. He founded D.E.E. Strategy Consulting, LLC, to advise health care clients. Mr. Ellingwood previously served as Senior Vice President of Strategy, Communications and Public Affairs for TriHealth, Inc. in Cincinnati, Ohio (November 2014 – July 2016) and as the Lead Executive for the Collective Impact on Health, The Health Collaborative (January 2014 – November 2014)(2014). From 1997 throughto 2013, Mr. Ellingwood served as Senior Vice President, Planning and Business Development for Cincinnati Children’s Hospital Medical Center.Center, following executive experience with the Spohn Health System in Corpus Christi, Texas (1990 – 1997) and as a health care consultant in Salt Lake City, Utah (1978 – 1990). The Board

		complex accounting and business issues, as well as his service to the Cincinnati community.
John M. Rice, Jr. Director since 2017 Age: 7072		John M. Rice is a Managing Director leading the Life Sciences practice at CincyTech, a firm that provides advice and capital to entrepreneurs, helps research institutions commercialize technology through startups,start-ups, and catalyzes investment from individuals and institutions to regional companies, having previously served as Director of Life Sciences since 2014. Dr. Rice is also the founder of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies, having served as Managing Partner from 2003 – 2018. He was previously a Managing Director at Senmed Medical Ventures from 1989 – 2003. In addition,his greater than 30 years in health care venture capital, Dr. Rice has served on the board of directors of severalmore than 25 privately-held health care companies.companies, currently chairing the boards of Genetesis, Kurome and Airway Therapeutics. In addition, he currently chairs the Investment Advisory Board of the Harrington Discovery Institute and serves on the board of Enable Injections. The Board believes that Dr. Rice’s scientific background and years of experience with a number of companies operating in the health care and related industries, as well as extensive experience within the capital markets, is extremely valuable to Meridian.

Our Audit Committee has appointed Ernst & Young LLP (“Ernst & Young” or “the Firm”) as our independent registered public accounting firm for the fiscal year ending September 30, 2022. In evaluating the appropriateness of engaging Ernst & Young as the Company’s independent registered public accounting firm, the Audit Committee considered a number of factors including, but not limited to: (i) Ernst & Young’s relevant technical expertise and its significant institutional knowledge of the Company’s operations and industry; (ii) the quality and candor of the Firm’s communications with the Audit Committee and management; (iii) the Firm’s independence, including the consideration of any non-audit

services provided and their impact on independence; (iv) the quality and efficiency of the services provided, including input from management on the Firm’s performance, objectivity and professional skepticism; (v) external data on audit quality and performance, including recent Public Company Accounting Oversight Board (“PCAOB”) reports on the Firm and its peer firms; (vi) the appropriateness of the Firm’s fees; and (vii) the Firm’s tenure as independent auditors, including the benefits of a longer tenure, and the controls and processes in place that help ensure the Firm’s continued independence. Ernst & Young has served as the Company’s independent registered public accounting firm since December 2020. Our Board has directed that this appointment be submitted to our shareholders for ratification. Although ratification of our appointment of Ernst & Young is not required, we are seekingvalue the opinions of our shareholders and believe that shareholder ratification of the Audit Committee’s selection of Grant Thornton LLPour appointment is a good corporate governance practice.

Ernst & Young also served as Meridian’sour independent registered public accountantsaccounting firm for the 2020 fiscal year. The affirmative voteyear ended September 30, 2021. Neither the Firm nor any of its members has any direct or indirect financial interest in or any connection with us in any capacity other than as our auditors, providing audit and non-audit related services. A representative of Ernst & Young is expected to virtually attend the Annual Meeting and to have an opportunity to make a majoritystatement and be available to respond to appropriate questions from shareholders. In the event that the appointment of shares voting at the meeting is required for ratification. If ratificationErnst & Young is not obtained,ratified by the shareholders, the Audit Committee intends to continue the engagement of Ernst & Young at least through the fiscal year ending September 30, 2022. Even if the appointment of Ernst & Young is ratified, the Audit Committee retains the discretion to appoint a different independent auditor at any time if it determines that such a change is in the interests of the Company.

Recent Change in Accounting Firm

Following a request for proposal (“RFP”) process, effective December 22, 2020 (the “Effective Date”), the Audit Committee of the Board of Directors of Meridian selected Ernst & Young as the Company’s independent registered public accounting firm for the Company’s fiscal year ended September 30, 2021. The Audit Committee dismissed Grant Thornton LLP at least(“Grant Thornton”), the Company’s then current independent registered public accounting firm, effective as of the Effective Date.

Grant Thornton’s reports on the Company’s Consolidated Financial Statements as of and for the fiscal years ended September 30, 2020 and 2019 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. During the fiscal years ended September 30, 2020 and 2019, and the subsequent interim period through fiscal 2020. Representativesthe Effective Date, there were: (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions between the Company and Grant Thornton on any matters of accounting principles or practices, consolidated financial statement disclosure, or auditing scope or procedure which, if not resolved to Grant Thornton’s satisfaction, would have caused Grant Thornton to make reference thereto in their reports; and (ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

The Company requested that Grant Thornton furnish a letter addressed to the SEC stating whether or not it agrees with the above statements, and, if not, stating the respects in which it does not agree. A copy of Grant Thornton LLP are expectedThornton’s letter agreeing with the above statements, dated December 28, 2020, was filed as Exhibit 16.1 to Meridian’s Form 8-K filed on or about December 30, 2020.

During the fiscal years ended September 30, 2020 and 2019 and the subsequent interim period through the Effective Date, neither the Company nor anyone on its behalf consulted with Ernst & Young regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be present atrendered on the meetingCompany’s Consolidated Financial Statements, and will be availableneither a written report nor oral advice was provided to makethe Company that Ernst & Young concluded was an important factor considered by the Company in reaching a statement, if they so desire,decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and to respond to appropriate questions asked by shareholders.the related instructions; or (iii) any “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Principal Accounting Firm Fees

Aggregate fees billed to Meridian by Ernst & Young and Grant Thornton LLP for fiscal years 20192021 and 20182020, as applicable, are listed below:

The Dodd-Frank Wall Street Reform and Consumer Protection Act (“Dodd Frank”), enacted in July 2010, requires that we provide our shareholders with the opportunity to vote to approve, on anon-binding, advisory basis, the compensation of our named executivesexecutive officers as disclosed in this proxy statement in accordance with the compensation disclosure rules of the Securities and Exchange Commission (“SEC”). Dodd Frank also provides that shareholders periodically be given the opportunity to vote, on anon-binding, advisory basis, for their preference as to how frequently we should seek future advisory votes on the compensation of our named executive officers. This opportunity was provided to our shareholders at our 2018 annual meeting, where over 80% of our voting shareholders voted to hold the“say-on-pay” advisory vote annually, in accordance with the recommendation of our Board of Directors. As a result, we are again holding asay-on-pay advisory vote at our 20202022 annual meeting, with the nextsay-on-pay advisory vote to be held at our 20212023 annual meeting.

As described below under the heading “Compensation Discussion and Analysis” beginning on page 1517 of this proxy statement, we seek to closely align the interests of our named executive officers with the interests of our shareholders. We structure our programs to discourage excessive risk-taking through a balanced use of compensation vehicles and metrics with an overall goal of delivering sustained long-term shareholder value, while aligning our executives’ interests with those of our shareholders. Further, our programs require that a substantial portion of each named executive officer’s compensation be contingent on delivering performance results that benefit our shareholders. Our compensation programs are designed to reward our named executive officers for the achievement of short-term and long-term strategic and operational goals and the achievement of increased total shareholder return.

The vote on this matter is not intended to address any specific element of compensation; rather, the vote relates to the overall compensation of our named executive officers, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC. The vote is advisory, which means that the vote is not binding on the Company, our Board of Directors or the Compensation Committee. The Board and the Compensation Committee will review and consider the voting results when making future decisions regarding our executive compensation program.

Accordingly, we ask our shareholders to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and disclosure.

The Board recommends that you voteFOR the approval of the compensation of our named executive officers as disclosed in this proxy statement.

CORPORATE GOVERNANCE

As an Ohio corporation, Meridian is governed by the corporate laws of Ohio. Since Meridian’s common shares are publicly traded on the Nasdaq Global Select Market, and it files reports with the SEC, it is also subject to Nasdaq rules and federal securities laws.

Board Leadership Structure

Governance of the corporationCompany is placed in the hands of the directors who, in turn, elect officers to manage the business operations. The Board oversees the management of Meridian on your behalf. The Board reviews Meridian’s long-term strategic plans and exercises direct decision making authority in all major decisions, such as acquisitions, the declaration of dividends, major capital expenditures and the establishment of certain company policies.

The Board operates and evaluates its performance in accordance with Corporate Governance Guidelines approved by the Board. These Guidelines are available aton our websitewww.meridianbioscience.com.

The Board is responsible for evaluating and determining Meridian’s leadership structure, and believes that at this point in time separate individuals should serve in the capacities of Chairman of the Board (“Chairman”) and Chief Executive Officer (“CEO”). It is the Board’s belief that such a structure provides the Company with the right foundation to pursue its strategic and operational objectives, while maintaining effective oversight and objective evaluation of the Company’s performance. These key executive positions are held byMr. Jack Kenny holds the position of CEO. Mr. David C. Phillips holds the position of Chairman of the Board, and Mr. Jack Kenny, CEO. Havinghaving served as a director since 2000,2000. However, on November 19, 2022, Mr. Phillips was appointed Chairmannotified the Company of his retirement as a director of the Company effective January 26, 2022. The Board uponintends to elect a new chairman when Mr. John A. Kraeutler retiring fromPhillips’ current term expires and will not replace the Company andvacated seat, which will reduce the Board effective September 30, 2018.number of directors to eight (candidates listed above). In his capacity as Chairman, Mr. Phillips ishas been responsible for: (i) general Board activities, including setting agendas for Board meetings and presiding over all meetings of the Board and shareholders; and (ii) providing advice and counsel to Meridian’s management regarding the Company’s business operations. As

CEO, Mr. Kenny is responsible for the general management, oversight, supervision and control of the business affairs of Meridian, and ensuring that all resolutions of the Board are put into effect.

In accordance with Nasdaq rules, our Board of Directors affirmatively determines the independence of each director and nominee for election as a director in accordance with the elements of independence set forth in the Nasdaq listing standards and Exchange Act rules. Meridian’s Director Independence Standards are available at our websitewww.meridianbioscience.com. Based on these standards, the Board has determined that each of the following members of the Board is independent: James M. Anderson, Anthony P. Bihl, Dwight E. Ellingwood, John C. McIlwraith, David C. Phillips, John M. Rice, Catherine A. Sazdanoff, and Felicia Williams.

During fiscal 2019,2021, the Board of Directors met on six14 occasions. The independent directors plan to meet as necessary during fiscal 20202022 without the presence of management directors. During fiscal 2019,2021, the independent members of the Boarddirectors met twofive times in executive session without the presence of management directors following regularly scheduled Board meetings. All of our directors attended at least 75% of the aggregate of all Board meetings and all meetings of Committees on which such directors served during fiscal 2019.2021.

Meridian expects all directors to attend shareholders’ meetings, and all directors attended the 20192021 Annual Shareholders’ Meeting.

Shareholders may communicate with the full Board or individual directors on matters concerning Meridian by mail or through our website,www.meridianbioscience.com, in each case to the attention of the Secretary,Vice President, Investor Relations, the address for whom is set forth on page 3134 of this proxy statement.

The Board’s Role in Risk Oversight

The Board of Directors, as a whole and also at the Committee level, plays a key role in operational risk oversight at Meridian and works with management to understand the risks the Company faces, the steps that management is taking to manage those risks and the level of risk appropriate for the Company in light of its overall business strategy. The Board approves the high level strategies, financial plans and policies of Meridian, setting the tone and direction for the appropriate levels of risk-taking within the organization.

While overall responsibility for risk oversight rests with the Board, it is the Audit Committee that has been given the primary responsibility of monitoring and evaluating the adequacy of management’s risk assessment and risk management practices. This role is carried out through its charter-mandated responsibilities related to Meridian’s: (i) overall financial risks and exposures; (ii) consolidated financial statement risks and exposures; (iii) financial reporting processes; (iv) compliance with ethics policies, such as the Code of Ethics, Employee Complaint Policy, Securities Trading Policies and the Foreign Corrupt Practices Act Policy; and (v) compliance with governmental and legal regulations, including those contained within the Sarbanes-Oxley Act. The Audit Committee provides regular

reports to the full Board and works closely with management to update the full Board, as necessary, on matters identified through these Committee risk oversight roles.

The Board has adopted a Code of Ethics applicable to Meridian’s officers, directors and employees. This Code of Ethics is posted onwww.meridianbioscience.com. Any amendments to or waivers fromof the Code of Ethics (to the extent permitted by Nasdaq Marketplace Rule 5610) will be posted on our website within four business days after the date of an amendment.

Committees of the Board of Directors

The directors have organized themselves into the standing Committees described below. Each of these Committees has a charter posted onwww.meridianbioscience.com. Meridian does not have an Executive Committee of its Board of Directors. The following table identifies membership and the Chairperson of each of the current standing committeesCommittees of the Board, as well as the number of times each committeeCommittee met during the fiscal year:

As previously noted on page 810 in “The Board’s Role in Risk Oversight” section, the Audit Committee also bears certain risk oversight responsibilities.

The Audit Committee has submitted the following report for inclusion in this proxy statement:

REPORT OF THE AUDIT COMMITTEE

The Audit Committee oversees Meridian’s financial reporting process on behalf of the Board. Management has the primary responsibility for the consolidated financial statements and the reporting process including the systems of internal controls over financial reporting. As part of the oversight processes, the Audit Committee regularly meets with management of Meridian, Meridian’s independent registered public accounting firm and Meridian’s finance and accounting personnel. The Audit Committee regularly meets with each of these groups separately in closed sessions. Throughout the year, the Audit Committee had full access to management, the independent registered public accounting firm and internal auditorsauditor for Meridian. To fulfill its responsibilities, the Audit Committee did, among other things, the following:

(a)

reviewed and discussed Meridian’s audited consolidated financial statements for fiscal 20192021 with Meridian’s management and the independent registered public accounting firm, including a discussion of the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the consolidated financial statements;

Respectfully submitted,

Audit Committee

Felicia Williams (Chair)

James M. Anderson

Catherine A. SazdanoffAnthony P. Bihl

David C. Phillips(Ex-Officio)

The Compensation Committee is comprised of James M. Anderson (Chair), Dwight E. Ellingwood,Anthony P. Bihl, John C. McIlwraith, and David C. Phillips(Ex-Officio) and is responsible for establishing compensation for Executive Officersexecutive officers and administering the Company’s compensation plans. As used in this proxy statement, “Executive Officer”“executive officer” means our chief executive officer, principalchief financial officer, principal accounting officer and any executive vice president. This includes establishing base salary levels and cash-based incentive plans, making stock-based awards, and otherwise dealing in all matters concerning compensation of the Executive Officers.executive officers. During fiscal 2019,2021, the Compensation Committee met fiveten times.

In general, the Compensation Committee annually reviews the Company’s compensation programs and its philosophy in setting performance targets each year. The Company provides the Compensation Committee with information on total compensation received for all Executive Officers,executive officers, including the sources of such compensation, for the immediately preceding fiscal year and recommendations for the current fiscal year. In discharging the responsibilities of the Board of Directors relating to compensation of the Company’s CEO and other Executive Officers,executive officers, the purposes of the Compensation Committee are, among others: (i) to review, set and approverecommend to the Board the compensation of the Company’s CEO and the Company’s other Executive Officers;executive officers; and (ii) to oversee the compensation policies and programs of the Company, including stock and benefit plans. The Compensation Committee’s specific functions include adopting, administering and approving the Company’s cash-based incentive compensation and

stock-based incentive plans and awards, including amendments to the plans or awards and performing such duties and responsibilities under the terms of any executive compensation plan, incentive-compensation plan or equity-based plan. The Compensation Committee has the authority to delegate any of its responsibilities to subcommittees as the Compensation Committee may deem appropriate in its sole discretion. The Compensation Committee has the authority to engage consultants and advisors. An independent consultant was engaged during fiscal 2018 to complete a compensation study of U.S. employees, a part of which was assisting the Company in evaluating and making recommendations related to the Company’s long-term incentive compensation plan. See discussion of the Long-Term Stock-based Incentives below on pages 16 and 19. The consultant provided a review of the competitiveness of the Company’s compensation ofnon-employee directors. In 2019,2021, the Committee also conducted a review of the CEO’s performance, reviewed the CEO’s assessment of his team’s performance, reviewed its Charter and conducted a self-assessment, facilitated by a third party.

The Compensation Committee determines the amount and mix of compensation components for the CEO, Mr. Kenny.Kenny, for recommendation to the Board. As CEO, Mr. Kenny provides recommendations to the Compensation Committee with respect to the compensation to be paid to the other Named Executive Officers.

To achieve corporate objectives, the Committee believes it is important to provide competitive levels of compensation in order to retain the most qualified employees, to recognize individuals who exceed expectations and to closely link executive compensation with corporate performance. The Committee believes Meridian’s long-term objectives can be achieved through a mix of cash-based incentive compensation plans and stock-based incentive compensation plans.

The Compensation Committee’s processes and procedures for the consideration and determination of executive and director compensation are discussed in the section entitled “Compensation Discussion and Analysis” in this proxy statement. See Compensation Committee Report on page 2227 following the Compensation Discussion and Analysis.

Compensation Committee Interlocks and Insider Participation

None of the members of the Compensation Committee has ever been an officer or employee of the Company. None of the members of the Compensation Committee is or was a participant in any related person transaction in fiscal 20192021 (see the section entitled “Transactions With Related Persons” in this proxy statement for a description of our policy on related person transactions). Lastly, none of the members of the Compensation Committee is an Executive Officerexecutive officer of another entity at which one of our Executive Officersexecutive officers serves on the Board of Directors. No Named Executive Officer of Meridian serves as a director or as a member of a committee of any company of which any of the Company’snon-employee directors are Executive Officers.executive officers.

The Nominating and Corporate Governance Committee consists of Catherine A. Sazdanoff (Chair), Dwight E. Ellingwood, (Chair), John C. McIlwraith, Catherine A. Sazdanoff,M. Rice, and David C. Phillips(Ex-Officio). The Committee met fivefour times during fiscal 2019. On2021. In November 4, 2019,2021, the Committee considered and recommended the nomination of the current directors forre-election.eight nominees identified in this proxy statement. The Committee identifies qualified nominees for the Board, recommends to the Board who will be nominated by the Company for election to the Board and recommends to the full Board any changes in the size of the Board. The Committee also reviewed its Charter and oversaw a third-party-facilitated self-assessment of the Board and its committees.Committees, the results of which are in process to be reviewed by the Nominating and Corporate Governance Committee.

In identifying, considering and recommending candidates for nomination to the nominationBoard, the Nominating and Corporate Governance Committee assesses the qualifications of directors,all candidates for the Committee takesBoard on an equal basis, taking into account, among other factors which it may deem appropriate, the judgment, skill, diversity, independence, and business experience of the potential nominee and the needs of the Board as its function relates to the business of the Company. The Committee considers candidates for nomination from a variety of sources including recommendations of shareholders. Shareholders desiring to submit recommendations for nomination by the Committee should direct them to the Chairman of the Nominating and Corporate Governance Committee in care of the Company at its address shown on the cover page of this proxy statement.

The Nominating and Corporate Governance Committee will assess the qualifications of all candidates for the Board on an equal basis. In identifying and considering candidates for nomination to the Board, the Committee considers, among other factors, quality of experience, the needs of the Company and the range of talent and experience currently represented on the Board. The Committee also discusses a director skills matrix, which it has prepared and periodically updates. The Committee evaluates such factors, among others, and does not assign any particular weighting or priority to any of these factors, nor does the Committee have a formal policy with respect to diversity. However, the Committee, working with the Board, considers the diversity of all of the Company’s stakeholders – including shareholders, employees and customers – when engaging in corporate governance discussions.

Additionally, during 2019, underThe Committee considers candidates for nomination from a variety of sources including recommendations of shareholders. Shareholders desiring to submit recommendations for nomination by the oversightCommittee should direct them to the Chair of the Nominating and Corporate Governance Committee an evaluationin care of the Board and Committees was performed by a third party. The resultsCompany at its address shown on the cover page of the evaluation were reviewed by the Board on November 5, 2019.this proxy statement.

DIRECTORS AND EXECUTIVE OFFICERS

This table listsidentifies the Executive Officersexecutive officers and Directorsdirectors of Meridian and shows the number of shares beneficially owned, as determined under SEC rules, on December 5, 2019.2, 2021. Beneficial ownership includes any shares as to which the individual has sole or shared voting or investment power and also any shares that the individual has the right to acquire within 60 days.

⁴ Tony Serafini-Lamanna joined Meridian in April 2018 as Vice President and General Manager of Diagnostics and was appointed Executive Vice President, Diagnostics in May 2020. Prior to joining Meridian, Mr. Serafini-Lamanna held various executive and management positions with Siemens Healthcare since 2001. Age: 58

⁵ Audit Committee Member.

⁶ Compensation Committee Member.

⁷ Nominating and Corporate Governance Committee Member.

⁸ Ex-Officio member of Audit, Compensation, and Nominating and Corporate Governance Committees.

* Less than one percent.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

The following table lists the persons known by the Company to be the beneficial owners of more than five percent of the Company’s common stock as of December 5, 2019,2, 2021, unless otherwise noted. Beneficial ownership includes any shares as to which the individual has sole or shared voting or investment power.

¹ For the beneficial owners listed in the table, the percentages listed reflect disclosures in the Schedule 13Gs most recently filed by each beneficial owner with the SEC as of the date of this proxy statement.

DELINQUENT SECTION 16(A) REPORTS

Section 16 of the Securities Exchange Act of 1934 requires Meridian’s Executive Officers,executive officers, directors and persons who own more than ten percent of a registered class of Meridian’s equity securities to file reports of ownership and changes in ownership with the SEC. Based on a review of the copies of such forms received by it, Meridian believes that during the last fiscal year, all of its Executive Officers,executive officers, directors and ten percent shareholders complied with the Section 16 reporting requirements except as described below. In making these statements, Meridian has relied upon examination of the copies of Forms 3, 4 and 5, and amendments thereto, and the written representation of its directors and Executive Officers.executive officers.

Lawrence J. Baldini, Melissa A. LuekeBryan T. Baldasare and Lourdes G. Weltzien each filed a late Formform 4 on February 25, 2019December 21, 2020 to report the sale of 407, 1,3041,991 and 1582,666 shares, respectively, to cover tax withholding arising from the vesting of equity awards that occurred on December 15, 2018November 16, 2020 for Mr. Baldini and Ms. Lueke,Baldasare, and on November 21, 201816, 2020 and November 23, 2020 for Dr. Weltzien. Dwight E. Ellingwood filed a late Form 4 on February 25, 2019 to report the acquisition of a total of 566 shares that had occurred through Mr. Ellingwood’s dividend reinvestment between February 2016 and November 2018. Bryan T. Baldasare filed a late Form 4 on September 23, 2019 to report a grant of 1,200 restricted stock units that was received on September 16, 2019.

TRANSACTIONS WITH RELATED PERSONS

Nasdaq rules require the Company to conduct an appropriate review of related party transactions required to be disclosed by the Company pursuant to SEC RegulationS-K Item 404 for potential conflict of interest situations on an ongoing basis and that all such transactions must be approved by the Audit Committee or another Committee comprised of independent directors. As a result, the Audit Committee annually reviews all such related party transactions and approves each related party transaction if it determines that it is in the best interests of the

Company. Additionally, the Audit Committee’s Charter provides it the authority to review, approve and monitor transactions involving the Company and “related persons” (directors and Executive Officersexecutive officers or their immediate family members, or shareholders owning five percent or greater of the Company’s outstanding stock). This also covers any related person transaction that meets the minimum threshold for disclosure in the proxy statement under the relevant SEC rules (generally, transactions involving amounts exceeding $120,000 in which a related person has a direct or indirect material interest). In considering the transaction, the Audit Committee may consider all relevant factors, including, as applicable: (i) the Company’s business rationale for entering into the transaction; (ii) the alternatives to entering into a related person transaction; (iii) whether the transaction is on terms comparable to those available to third parties, or in the case of employment relationships, to employees generally; (iv) the potential for the transaction to lead to an actual or apparent conflict of interest and any safeguards imposed to prevent such actual or apparent conflicts; and (v) the overall fairness of the transaction to the Company. This policy is included in the Company’s Employee Handbook. The approvals of such related person transactions are evidenced by internal Company resolutions, minutes or memoranda.

COMPENSATION DISCUSSION AND ANALYSIS

Throughout this proxy statement, the individuals who served as the Company’s CEO and Chief Financial Officer during fiscal 2019,2021, as well as the other individuals listed in the Summary Compensation Table below, are referred to as the “Named Executive Officers” or “NEOs.”

Compensation Philosophy and Objectives

Our executive compensation is tied to performance objectives that are aligned with our strategic objectives to incentivize and focus behavior on strengthening our business forcreating long-term shareholder value. Meridian believes that peopleemployees who understand our purpose will drive progress. In order to create value for our shareholders, it has been important for us to focus on the core areas of growth, cost containment and organizational development. We continued to transform our business resources in 2019,2021, based on where towe believe we can better compete in the market and better leverage our strengths across the globe. Our strategic priorities are as follows:

Compensation and benefit programs are an important part of the Company’s employment relationship, which also include challenging and rewarding work and a focus on career growth, while aligning with our strategy of increasing shareholder value. Pay for performance is fundamental to our compensation philosophy. We reward individuals’ performance for contributions to business success.

Critical to each element of our total compensation and benefits philosophy is that it be based on a strategy to attract, retain, and unlock the hidden potential of our human capital, and it therefore consists of competitive base pay, incentive programs, and benefits that meetprovide income security and protection. The affordability of compensation and benefits are considered over the medium- to long-term, and to the extent possible, will not fluctuate based on short-term business conditions.

The key principles to the design of our compensation programs are as follows:

Base salaries are based on individual job duties, performance and achievements, while considering internal pay equity, retention, critical skills, and independent survey market data for specific regions.data. Annual cash-based incentive programs are based on defined metrics aligned to our strategic objectives and the achievement of performance goals that are set at levels to motivate executives to commit to growth and align with shareholder value creation, while improving performance.

Stock-based incentive awards consisthistorically consisted of restricted stock units andnon-qualified stock options, with vesting generally being time-based. During November 2021, the Company adopted a performance-based restricted stock unit program as discussed below. Stock-based awards are designed to both reward and retain, while aligning interests of management with our shareholders.

The Compensation Committee has established several principles and practices that are important to achieving our compensation philosophy and objectives. These are summarized below.

Gross-up Payments, Repricing of Options, Pledging, Hedging and Margin Accounts

The Company avoids new contractual agreements that include excise taxgross-up payments. It does not allow the repricing of options, which is not permitted under the 2012 Stock Incentive2021 Omnibus Award Plan without first obtaining the approval from shareholders of the Company. Additionally, the Company’s Insider Trading Policy places restrictions on the Company’s directors and Executive Officersexecutive officers regarding entering into hedging transactions with respect to the Company’s securities and from holding the Company’s securities in margin accounts or otherwise pledging such

securities as collateral for loans. Specifically, our Insider Trading Policy provides that directors, Executive Officersexecutive officers and certain other designated employees may not purchase Meridian securities on margin or borrow against any account in which Meridian securities are held. The Policy also provides that such persons may not pledge Meridian securities as collateral for a loan or engage in hedging or monetization transactions (such aszero-cost collars and forward-sale contracts) with respect to Meridian securities. No directors or Executive Officersexecutive officers have in place any pledges or hedging transactions.

Recovery of Past Awards

With respectThe Board has adopted a compensation recoupment or “clawback” policy, applicable to all officers subject to Section 16 of the Securities Exchange Act of 1934. Under this policy, the Company will pursue recoupment of any excess compensation, including incentive cash bonuses, restricted stock unit awards, stock options or other compensation, which was awarded to a covered officer based on financial statements of the Company where such statements are required to be restated as a result of the intentional misconduct or fraud of the covered officer. In addition to recoupment, the Company shall take such other remedial actions deemed necessary against a covered employee, including recommending disciplinary actions up to and including termination and other available remedies. The recovery period for recoupment of past awards, except as provided by applicable lawsany compensation is up to two fiscal years preceding the date on which the Company is required to prepare and regulations, we do not have afile the restated financial statements. This policy has been proactively adopted in advance of final guidance under Section 954 of the Dodd-Frank Act and will be amended to conform with respect to adjustment or recovery of awards or payments if relevant Company performance measures upon which previous awards were based are restated or otherwise adjusted in a manner that would reduce the size of such award or payment. Under those circumstances, we expect that the Compensation Committee and the Board would evaluate whether compensation adjustments are appropriate based upon the facts and circumstances surrounding the applicable restatement or adjustment.this Section when final guidance is available.

Minimum Vesting Periods

AlthoughAwards granted under the plan document for our 2012 Stock Incentive2021 Omnibus Award Plan, does not includeother than cash-based awards, are generally subject to minimum vesting periods for options or stock appreciation rights, our Compensation Committee includes minimum vesting provisions in the award agreements for stock options pursuant to authority granted to it under the 2012 Stock Incentive Plan. Generally the option award agreements provide for a minimum vesting periodrequirements of three years.one year. The 2012 Stock Incentive2021 Omnibus Award Plan also provides that no restricted stock or restricted stock units conditioned upon the achievement of performance objectives shall be based on a restriction period of less than one year, subject to the Plan’s provisions applicable to termination of employment and change in control.

Cash Buyouts of Underwater Options

Although the plan document for our 2012 Stock Incentive2021 Omnibus Award Plan does not include a provision expressly prohibiting cash buyouts of options or stock appreciation rights, the Compensation Committee believes cash buyouts of

“underwater “underwater options” is a governance practice that investors view as unfavorable. As a result, the Compensation Committee is generally opposed to cash buyouts of options or stock appreciation rights.

Back-Dating and Spring-Loading

Although Meridian does not have a written policy regarding the timing or practices related to granting equity awards, neitherNeither Meridian nor the Compensation Committee engages in spring-loading, back-dating or bullet-dodging practices. Equity awards are generally granted byMeridian’s Board has adopted a policy that provides that the Compensation Committee inmay grant equity awards to Company employees (executive officers, vice presidents, senior directors and directors) for the first quarterCompany’s annual equity compensation grant cycle only during the period of the fiscalOctober 20 through November 10 each year. Stock options are granted at the closing market price on the date of grant, pursuant to the 2012 Stock Incentive Plan.grant. Prior to the exercise of an option, the holder has no rights as a shareholder with respect to the shares subject to such option, including no rights to vote or to receive dividends. Restricted stock units do not have voting rights.

Ownership Guidelines

Consistent with its compensation philosophy and the principle of aligning the interests of management and directors of the Company with the interests of its shareholders, the Board of Directors has implemented stock ownership guidelines for “Specified Officers” (defined in the guidelines as those officers required to file beneficial ownership reports with the SEC) andnon-employee directors. Under the guidelines, the Company’s CEO is required to own an amount of Company common stock (includingnon-vested restricted stock units) which is equal to or exceeds three times such CEO’s annual base salary, and Specified Officers other than the CEO are required to own an amount of Company common stock (includingnon-vested restricted stock units) which is equal to or exceeds such officer’s annual base salary. Also, under the guidelines, each of the Company’snon-employee directors is required to own an amount of Company common stock which is equal to or exceeds three times suchnon-employee director’s annual retainer. Generally, persons subject to the guidelines are required to achieve the

applicable guideline not later than three years from the appointment to their position. Excluding certain of those who are still within thephase-in period, asAs of the date of this proxy statement, persons subject to these guidelines have been deemed by the Board to have met their ownership target, either as a result of their direct holdings or shares held indirectly by an entity affiliated with such person, in accordance with the guidelines.

The Compensation Committee is responsible for ongoing oversight of compliance with this compensation philosophy. The Compensation Committee ensures that the total compensation paid to the NEOs is fair, reasonable and competitive.

At our 20192021 annual meeting, Meridian once again held an advisory vote on the compensation of its NEOs, commonly referred to as asay-on-pay vote. Our shareholders approved the compensation of our NEOs, with approximately 97%86% of votes cast in favor of our 20192021 say-on-pay resolution. Based on the results of the 20192021 say-on-pay vote, the Compensation Committee concluded that the compensation paid to the NEOs and Meridian’s overall pay practices received strong shareholder support and do not require substantial revision to address shareholder concerns.

Executive Summary

Fiscal 2021 Highlights

Fiscal 2021 was a second consecutive record year for Meridian for reported net revenues and earnings. Actions of management over the previous two years prepared the Company to both weather the effects of the COVID-19 pandemic storm in Diagnostics and excel as a critical supplier to the IVD industry battling the global COVID-19 pandemic. The Compensation Committee recognized the following achievements of the Company during fiscal 2021 as it considered the Company’s compensation philosophy and related decisions related to executive compensation:

Actions of the Compensation Committee

In several meetings during the year, Mr. Kenny and the Compensation Committee Chairman discussed, among other things, Meridian’s compensation philosophy and its effectiveness in attracting and retaining talented employees. They also discussed certain changes to the compensation programs for fiscal 20192021, which are outlined in this proxy statement.

At its 20192021 meetings, the Compensation Committee discussed these matters, both with and without the presence of management. The Compensation Committee discussed the recommendations of the CEO for compensation

levels for all officers and the general pay increases to be paid throughout the Company. The Committee then made the compensation decisions, which are reflected in the figures presented in this proxy statement.

Fiscal 20192021 Compensation Decisions

For fiscal 2019,Fiscal 2021, the target payout ratios as a percentage of base salary for the original Cash-Based Incentive Compensation Plan’s target payout ratioPlan (“CICP”) were fifty percent (50%) for the NEOs other than the CEO, was thirty-fiveand ninety percent of base salary, with forty(90%) for the CEO. Thirty percent (30%) of the target payout ratio (14%)was based on achieving certain levels of net revenues; fortythirty percent (30%) of the target payout ratio (14%)was based on achieving certain levels of non-GAAP operating income (seenon-GAAP financial measure reconciliation below);income; and the remaining twentyforty percent of the target payout ratio (7%(40%) was based on individual performance using a1-5 rating system. The specific minimum levelsBusiness Accelerator and Individual Performance Kickers were aimed at rewarding performance for net revenues achievement and growth significantly above our original financial guidance published in November 2020 and our internal operating plan. The Kickers were not achieved for Fiscal 2021; however, the CICP under the original plan design achieved actual revenue and income of revenues,non-GAAP operating income135% and 150% of the targets, respectively. The individual performance ratings required to achieve the varying percentage of target payoutachievements for each measurement criteria are as follows:

The cash-based incentive compensation payments received by the NEOs other than the CEO ranged from 75% to 125%, and for fiscal 2019, as reflectedthe CEO was 108%, resulting in the Summary Compensation Table, were based on the Company achieving: (i) revenues totaling approximately $201,000,000 (no payout);non-GAAP operating income totaling approximately $43,500,000 (50% of target payout); and (iii) individual performance ratings of 3.actual payout percentages shown below.

Following is a reconciliation of GAAP operating income to non-GAAP operating income achieved relative to the targets listed above was adjusted to take into consideration the operating costs from the acquisition of the GenePOC business, as this acquisition occurred subsequent to the determination of the operating income targets.for fiscal 2021:

The cash-based incentive compensationCICP payment for the CEO was determined by the Compensation Committee pursuant to the terms of Mr. Kenny’s employment agreement, as well as taking into consideration actual net revenues andnon-GAAP operating income achieved, relative to the original targets and the Business Accelerator Kicker and Individual Performance Kicker thresholds noted above. Similar toin the NEOs other than the CEO, the Compensation Committee’s determination for the CEO took into consideration the operating costs from the acquisition of the GenePOC business, as this acquisition occurred subsequent to the determination of the operating income targets.table above.

Fiscal 20202022 Compensation Decisions

Base Salaries

Based on our financial results in fiscal 20192021 and the Compensation Committee’s review of the CEO’s evaluation of the other NEOs, theup-comingmerit increaseincreases for Dr. Weltzien isand Mr. Serafini-Lamanna for fiscal 2022 are expected to be approximately 3%. As a result of his promotion and base salary adjustment on October 1, 2019, Mr. Baldasare will not receive a merit adjustment on January 1, 2020. With respect to Mr. Kenny, see page 21 for discussionwhose employment agreement has an October 1^st anniversary, the Compensation Committee approved a 3% merit increase effective October 1, 2021 based on the Compensation Committee’s evaluation of his compensation arrangements.Mr. Kenny’s performance during fiscal 2021. Base salaries across all Meridian employees below the executive level are expected to increase approximately 3% effective January 1, 2020.

Cash-Based Incentive Compensation

The Compensation Committee approved the 2020 Cash-Based Incentive Compensation Plan2022 CICP structure, including performance targets and payout targets. For NEOs other than the CEO, theThe target payout ratio is forty percentratios as a percentage of base salary. Forsalary are fifty-five percent (55%) for the NEOs other than the CEO, thirtyand ninety-five percent (95%) for the CEO. Thirty percent (30%) of the target payout ratio (12%) is based on achieving certain levels of net revenues; thirty percent (30%) of the target payout ratio (12%) is based on achieving certain levels of non-GAAPoperating income; and the remaining forty percent of the target payout ratio (16%(40%) is based on individual performance.performance using a 1-5 rating system. Depending on the level of achievement, a NEO other than the CEO may earn from 0% to 68% of base salary. For the CEO, the targetpay-out ratio is seventy-five percent93.5% of base salary, pursuantand the CEO may earn from 0% to the provisions161.5% of Mr. Kenny’s amended employment agreement.base salary.

Cash-based incentive compensation, if earned, is paid in the first quarter of each fiscal year, for the prior fiscal year’s performance. The net revenues and operating income targets operate independently.independently from one another. While the net revenues portion may be earned upon achieving the net revenues targets, the component related to operating income is subject to the Company’s attainment of the specific operating income target, after inclusion of the compensation expense related to cash-based incentive compensation. Should the Company fail to reach the minimum operating income target, generally, no cash-based incentive compensation will be paid for this component.

Management and theThe Compensation Committee have intended thathas designed the net revenues and operating income thresholds to be set at reasonably achievable targets, yet at levels that require diligence to produce meaningful performance. The Compensation Committee tends to set the thresholds consistent with thehas also established “kickers” that are aimed at rewarding performance for net revenuerevenues achievement and growth significantly above our financial guidance and internal operating plan, while maintaining a minimum non-GAAP operating income guidance range.margin of at least 22%. Such “kickers” are effective at revenues ranging from $325 million to $370 million. At $325 million, a NEO other than the CEO could earn as much as 96.8% of base salary, and the CEO could earn as much as 167.2% of base salary. At $370 million, a NEO other than the CEO could earn as much as 126.5% of base salary, and the CEO could earn as much as 218.5% of base salary. At kicker levels of $340 million and above, maximum kicker amounts for a given level are subject to a business unit achieving at least 100% of its $150 million net revenues plan, and the achievement of an individual performance rating of 3 or higher on the 1-5 rating system.

Long-Term Stock-based IncentivesStock-Based Incentive Compensation

After considering the independent consultant’s findings and recommendations, the Compensation Committee has modified the Company’s long-term stock-based incentive program. As a result of these modifications, awardsAwards to be granted to certain executives of the Company, including the NEOs other thanand the CEO, are based on fixed dollar values that are dependent uponon the executive’s level in the Company. Such awards are expected to behave historically been in the form of restricted stock units. Awards to be granted to the CEO will be governed by the provisions of Mr. Kenny’s amended employment agreementunits, and are expected to include two types of equity awards,in some cases, non-qualified stock options, that vested over certain service periods. In November 2021, performance-based restricted stock units (“PSU”) were granted to certain executives, including the NEOs and optionsCEO, based on fixed dollar values that are dependent on the executive’s level in the Company. The performance conditions in these awards are based on a range of net revenues for each business unit and non-GAAP consolidated operating income before consideration of stock-based compensation expense, each to purchase Company stock.be measured for the Company’s fiscal 2024.

For Life Science, the foundational principles underlying the performance metrics include a larger scale of net revenues in a post-pandemic world, fueled by innovative new products and broad penetration within industrial customers (IVD manufacturers, veterinary, environmental, ag-bio, etc.), while generating non-GAAP operating profit margin at 50% or higher.

For Diagnostics, the foundational principles underlying the performance metrics are intended to evidence that this business has completed a turnaround from its pre-fiscal 2019 lack of investment vulnerabilities, has fully recovered from the LeadCare^® product recall situation, and has begun generating respectable returns from major investments to re-freshen its product portfolio and improve manufacturing efficiencies. These foundational principles contemplate success with commercial execution, new product clearances and launches, and manufacturing efficiencies.

Each business unit has a range of net revenues targets, as well as the consolidated non-GAAP operating income before consideration of stock-based compensation measurement, for fiscal 2024 that trigger a given level of PSU Award payout as follows:

¹ Payout percentage scale is intended to be at a graduated pro rata rate between 50% and 100%, and 100% and 200%.

Given that the PSU Award program has a mix of net revenues and non-GAAP operating income targets, any mix which could be met or none at all, the table below summarizes the formula to allocate the award payouts across the financial targets.

Establishing Compensation Levels

The Compensation Committee reviews, sets and recommends CEO compensation to the Board of Directors for approval.approval the compensation of the CEO. The Company has an employment agreement with the CEO, which is described on page 21.27. The compensation levels for the other NEOs are recommended by the CEO. The Compensation Committee has discretion to follow or modify such recommended levels of compensation. The Compensation Committee considers the input of our CEO as a crucial component of its compensation processes and decisions relating to NEO compensation. The Compensation Committee is not obligated to follow his recommendations. The Company does not engage in strict numerical benchmarking in determining the percentage modifications for the NEOs.

Under its charter, the Compensation Committee is authorized to engage outside advisors at the Company’s expense. In fiscal 2018,2021, the Company engageddid engage an independent consultant to completeprovide benchmarking data from a selected peer group and provide counsel on the levels of compensation studyand benefits for U.S. employees, a partexecutives, including the individual components thereof. The peer group was selected based on several criteria: industry sector and therapeutic focus, market capitalization, employee headcount and trailing 12 months’ net revenues. Recommendations from the independent consultant led to: (i) implementation of which was assisting the Company in evaluating, and making recommendations relatedPSU Award program discussed herein; (ii) increases to the targeted percentage payouts under the Company’s long-term incentiveCICP (annual cash-based incentives); and (iii) changes in vesting for equity awards that vest based on future employee service.

The following table summarizes the key changes to executive compensation including providing benchmarked peer data of such compensation. See discussionresulting from the counsel of the long-term incentive compensation above.independent consultant:

In setting the NEOs’ compensation, the Compensation Committee reviews all components of such compensation through the use of tally sheets. These tally sheets provide the amount of total compensation paid or earned by each NEO based on his or her base salary, cash-based incentive compensation, stock-based awards and retirement contributions. The tally sheets reviewed provide all of the information that is reflected in the Summary Compensation Table. The review by the Compensation Committee analyzes how changes in any element of compensation would impact other elements, particularly severance or change in control benefits, if applicable to the executive. Such analysis has become an important component in the Compensation Committee’s review of executive compensation, as the tally sheet allows the Compensation Committee to consider an executive’s overall

compensation rather than only one or two specific components of an executive’s compensation. This allows the Compensation Committee to make compensation decisions and evaluate management recommendations based on a complete analysis of an executive’s total compensation. Salaries are set on a calendar year basis and, therefore, salaries paid in the first three months of each fiscal year beginning on the first day of October are set in the prior fiscal year.

The selected peer group used by the independent consultant referred to above was as follows:

Components of Executive Compensation and Related Risk Profile

Meridian’s executive compensation and benefits packages consist of base salary, cash-based incentive compensation, long-term stock-based incentive awards, Company-sponsored benefit and retirement plans, and change in control severance benefits. Each of these components has a certain risk profile.

The Compensation Committee has reviewed the risk profile of the components of the Company’s executive compensation program, including the performance objectives and target levels used in connection with incentive awards, and has considered the risks a NEO might be incentivized to take with respect to such components. When establishing the mix among these components, the Compensation Committee is careful not to encourage excessive risk taking. Specifically, the performance objectives contained in the Company’s executive compensation programs have been balanced between annual and long-term incentive compensation to ensure that bothall components are aligned and consistent with our long-term business plan and that our overall mix of stock-based awards has been allocated to promote an appropriate combination of incentive and retention objectives.

The Compensation Committee believes that the Company’s executive compensation program does not incentivize the NEOs to engage in business activities or other behavior that would threaten the value of the Company or the investments of its shareholders.

The Compensation Committee continues to monitor and evaluate on anon-going basis the mix of compensation, especially equity compensation, awarded to the NEOs, and the extent to which such compensation aligns the interests of the NEOs with those of the Company’s shareholders. In connection with this practice, the Compensation Committee has, from time to time, reconsidered the structure of the Company’s executive compensation program and the relative weighting of various compensation elements.

See Executive Summary on page 1720 for discussion of base salaries, annual cash-based incentive compensation and long-term stock-based compensation.

Company-Sponsored Benefit and Retirement Plans

Meridian provides Company-sponsored benefit and retirement plans to the NEOs. In general, executives participate in the Company’s benefit and retirement plans on the same basis as other Company employees. The core benefit package includes health, dental, shortshort- and long-term disability, and group term life insurance. Meridian generally provides retirement benefits to executives through qualified (under the Internal Revenue Code) defined contribution plans (401K Plan).

Change in Control Severance Benefits

The Compensation Committee believes that a reasonable level of salary and Company-sponsored benefit protection provides a means of retention and allows the NEOs to remain focused on achievement of Company goals and objectives in the event that the Company becomes subject to a merger or acquisition transaction. This component of compensation would only be paid in the event of a change in control of the Company, under certain qualifying conditions, and termination of the NEO’s employment (i.e., double trigger). For the CEO and otherthe NEOs, this component of compensation would include two years’ base salary, performance bonus and core benefits. See page 2932 for a description of change in control severance agreements entered into with our Executive Officers.executive officers.

Jack Kenny Employment Agreement

On November 5, 2019, Meridian entered into an Amended and Restated Employment Agreement (the “Kenny Employment Agreement”) with Jack Kenny, its CEO. Under the Kenny Employment Agreement, Mr. Kenny is entitled to be paid a base salary of $670,000 and his salary shall be reviewed annually by the Compensation Committee. During the first year of the Kenny Employment Agreement, Mr. Kenny iswas eligible to earn an annual target bonus of seventy-five percent (75%) of his base salary. Thereafter, the Compensation Committee shall set an eligible target amount for the annual bonus for the applicable employment term year. For fiscal 2022, the target bonus has been set at ninety-five percent (95%) of base salary. The actual amount of any annual bonus payable to Mr. Kenny in any year shall be determined by the Compensation Committee based upon performance criteria set forth in advance under the bonus plan established by the Compensation Committee and the achievement of such performance criteria.

As contemplated by the Kenny Employment Agreement, on November 5, 2019 the Company granted Mr. Kenny pursuant to Meridian’s 2012 Stock Incentive Plan: (i) options to purchase 198,119 shares of common stock of the

Company, which shall vest on a pro rata basis over three years; and (ii) 99,505 restricted stock units, which shall vest in a lump sum or “cliff” basis on October 1, 2022.

The effective date of the Kenny Employment Agreement is October 1, 2019 and its term is two years, with annual renewal provisions following the initial term. Either the Company or Mr. Kenny may terminate the Kenny Employment Agreement at any time for any reason upon 90 days’ notice. In the event that the Company terminates the employment of Mr. Kenny without Cause or if he terminates his employment for Good Reason, each as defined in the Kenny Employment Agreement, Mr. Kenny is entitled to a severance payment equal to twelve months of his then current base salary plus apro-rata portion of the target bonus through the date of termination. If such termination occurs during a change in control period (i.e., a double trigger), Mr. Kenny is entitled to a severance payment equal to two times his then current base salary plus his target bonus for the year in which the termination occurs.

The Kenny Employment Agreement contains customary indemnification provisions and a “clawback” provision that enables the Company to recoup any amounts paid to Mr. Kenny under the Kenny Employment Agreement if so required by applicable law or any applicable securities exchange listing standards.

Melissa A. Lueke Consulting Agreement

The Company and Ms. Lueke, our former Chief Financial Officer, entered into a Consulting Agreement effective January 1, 2019 upon her retirement from the Company. The Consulting Agreement provides that Ms. Lueke will assist the Company on anas-requested basis with matters related to the Company’s financial reporting and accounting, among other matters. Under the Consulting Agreement, the Company agreed to pay Ms. Lueke $90,000 per year and reimburse her for certain expenses. The Consulting Agreement’s term is three years and may be renewed upon mutual written agreement or cancelled by Ms. Lueke at any time.

Internal Pay Equity

The Compensation Committee believes that the relative difference between the CEO’s compensation and the compensation of the Company’s other executives has not increased significantly over the years.is appropriate. Further, the Compensation Committee believes that the Company’s internal pay equity structure is appropriate based upon the contributions to the success of the Company and as a means of motivation to other executives and employees.

COMPENSATION COMMITTEE REPORT

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of RegulationS-K with management. Based on these reviews and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the Company’s proxy statement on Schedule 14A.

Members of the Compensation Committee

James M. Anderson (Chair)

Dwight E. EllingwoodAnthony P. Bihl

John C. McIlwraith

David C. Phillips(Ex-Officio)

CEO PAY RATIO

Our CEO Pay Ratio was calculated in compliance with the requirements set forth in Item 402(u) of RegulationS-K. We identified the median employee population as of July 31, 2019,2021, which included all 660730 global full-time, part-time, temporary and seasonal employees employed on that date, excluding 1826 such employees in our Belgium, China, France and Holland locations, which in the aggregate represent less than 5% of our workforce.    We used a consistently applied compensation measure across our global employee population to calculate the median employee compensation. For our consistently applied compensation measure, we utilized total cash compensation per our internal payroll records, annualized and translated to U.S. dollars. We then calculated the median employee’s fiscal 20192021 compensation in the same manner as the NEOs in the Summary Compensation Table. Our median employee compensation for fiscal 20192021 was $59,227$71,837 and our CEO’s compensation was $1,316,392.$3,233,705. Accordingly, ourCEO-to-Employee Pay Ratio is 22:approximately 45:1.

EQUITY COMPENSATION PLAN INFORMATION

The following table presents information about the Company’s equity compensation plans as of September 30, 2019 (number of securities information in thousands):

SUMMARY COMPENSATION TABLE

The following table summarizes the aggregate compensation paid, or earned, by each of the NEOs for the fiscal years ended September 30, 2019, 20182021, 2020 and 2017,2019, respectively:

Executive Vice President and Chief Financial Officer. A discussion of the assumptions used in calculating these values may be found in Note 7(b) on page 612 The amounts shown reflect the grant date fair value of the restricted stock units issued during fiscal years 2021, 2020 and 2019 in accordance with ASC Topic 718, including those granted to Mr. Kenny in connection with his November 5, 2019 Employment Agreement. In addition, the amounts reflected for Mr. Baldasare and Mr. Serafini-Lamanna in fiscal 2019 include the grant date fair value of restricted stock units granted in connection with the acquisition of GenePOC, Inc. A discussion of the assumptions used in calculating these values may be found in Note 12(b) on page 67 of the Company’s Annual Report on Form10-K filed with the SEC on November 23, 2021. filed with the SEC on November 26, 2019.

4	The amounts shown represent amounts earned by the NEOs pursuant to the Officer’s Performance Compensation Plan for fiscal 2019 and 2018. No such amounts were earned for fiscal 2017, as the corporate-wide targets were not reached for this fiscal year.

5	See the All Other Compensation table below for amounts, which include certain Company contributions and other personal benefits for fiscal 2019.

³ The amounts shown reflect the grant date fair value of the stock options granted during fiscal years 2021 and 2020 in accordance with ASC Topic 718, including those granted to: (i) Mr. Kenny in connection with his

November 5, 2019 Employment Agreement; and (ii) Mr. Serafini-Lamanna in connection with retention grants made to members of the Executive Leadership Team, excluding Mr. Kenny, Mr. Baldasare and Dr. Weltzien, in March 2020, prior to his promotion to Executive Vice President. A discussion of the assumptions used in calculating these values may be found in Note 12(b) on page 67 of the Company’s Annual Report on Form 10-K filed with the SEC on November 23, 2021.

⁴ The amounts shown represent amounts earned by the NEOs pursuant to the Officer’s Performance Compensation Plan for fiscal 2021, 2020 and 2019.

⁵ The amounts shown represent Retirement Contributions made by the Company on behalf of the NEOs.

⁶ Mr. Baldasare was named Executive Vice President and Chief Financial Officer of Meridian effective October 1, 2019.

⁷ Mr. Serafini-Lamanna was named Executive Vice President, Diagnostics effective May  18, 2020.

GRANTS OF PLAN-BASED AWARDS

The following table sets forth, for each of the NEOs, information related to grants made during fiscal 20192021 under Meridian’s Cash-Based Incentive Compensation Plan and 2012 Stock Incentive Plan: